ALBANY, New York, October 3, 2016 /PRNewswire/ --
The global intravenous immunoglobulin (IVIG) market is largely consolidated, with top four players: Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, accounting for over 70% of the overall market in 2015. Grifols S.A. accounted for the dominant share of 23.0%, chiefly on account of the company's strong geographic penetration.
Transparency Market Research estimates that the global intravenous immunoglobulin (IVIG) market, which was valued at US$7.23 bn in 2015, is projected to expand at a CAGR of 8.5% from 2016 to 2024 and reach US$14.92 bn in 2024. In terms of end users, the hospitals segment is presently leading, accounting for a more than 62% of the overall market in 2015. The segment is, however, expected to lose prominence to the home care segment and reflect a loss in its overall share by 2024. In terms of geography, North America, which presently accounts for over 45% of the global market, is expected to retain dominance by 2024 as well.
Browse Research Report with Full TOC: http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Oligopoly in the market has led to intense competition among top players and has compelled companies to take course of strategic mergers and acquisitions and geographic expansions. Point in case is the CSL Behring LLC's geographic expansion by opening operations in Russia in December 2015. The company stated that the expansion was driven by large unmet need of quality biotherapeutics and blood plasma products in the country.
Rising Prevalence of Neurological Diseases to Boost Global Demand for IVIG Products
The rapidly rising prevalence of a variety of hematological and neurological disorders such as alloimmune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), and myasthenia gravis is the chief factor driving the intravenous immunoglobulin (IVIG) market. For instance, the occurrence of myasthenia gravis in the U.S. has been assessed at 14 to 20 cases out of 100,000 people, which comes to around 36,000 to 60,000 cases in the country. This neuromuscular transmission has a high probability of remaining undiagnosed and thus the prevalence of this disease is actually much higher. Over 40% of the world's IVIG products are used to treat neurological diseases, thus the rising prevalence of neurological disorders is a highly significant factor of growth for the global IVIG market.
Moreover, the mounting global population of geriatrics, which is more vulnerable to diseases due to poor immunity, is also a key factor driving the IVIG market. According to the WHO, the global geriatric population is expected to increase from 524 mn in 2010 to 1.5 bn by 2050. This is anticipated to drive the increased demand for better immunological treatments, which in turn would provide opportunities for companies operating in the global intravenous immunoglobulin market. The steady rise in the use of intravenous immunoglobulin for the treatment of off-label indications a significant rise in the blood plasma yield across the globe are also likely to drive the intravenous immunoglobulin (IVIG) products market.
Request a PDF Brochure of this Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
High Cost of Treatment and Potential Side Effects to Hamper Market Growth
One of the key challenges that could hamper the overall development of the global IVIG market is the comparatively much higher cost of plasma collection and manufacturing processes as compared to conventional pharmaceutical manufacturing and processing products. Moreover, immunoglobulin products being derivatives of blood, they require highly sophisticated methods and equipment for collection, purification, and storage. This scenario adds to the overall cost and complexity of IVIG products and therapies.
Intravenous immunoglobulin (IVIG) preparations also have several related side effects, which could lead to serious health problems in some patients. Owing to this, patients are sometimes discouraged from continuing IVIG therapies. Side effects associated with the use of IVIG also sometimes encourage clinicians to opt for alternate therapies. This factor is likely to restrain the overall development of the intravenous immunoglobulin (IVIG) market in the next few years.
This review of the market is based on a recent market research report published by Transparency Market Research, titled "Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024."
Browse Press Release on Global Intravenous immunoglobulin (IVIG) Market:
For this study, the global IVIG market is segmented as follows:
Global Intravenous immunoglobulin (IVIG) Market, by Indication
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Primary Humoral Immunodeficiency
- Idiopathic Thrombocytopenic Purpura (ITP)
- Guillain-Barre Syndrome
- Myasthenia Gravis
- Multifocal Motor Neuropathy (MMN)
- Kawasaki Disease
- Chronic Lymphocytic Leukemia
Global Intravenous immunoglobulin (IVIG) Market, by End-user
- Home Care
Global Intravenous immunoglobulin (IVIG) Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Browse Other Research Reports:
- Geriatric Care Services Market: http://www.transparencymarketresearch.com/geriatric-care-services-market.html
- Plasma Protein Therapeutics Market: http://www.transparencymarketresearch.com/plasma-protein-therapeutics-market.html
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
SOURCE Transparency Market Research